46.45 0.00 (0.00%)
After hours: 4:44PM EST
|Bid||45.45 x 800|
|Ask||46.50 x 1100|
|Day's Range||45.01 - 46.49|
|52 Week Range||19.20 - 53.70|
|Beta (3Y Monthly)||2.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017
Novocure will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts.
Novocure (NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Novocure (NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology. The analysis demonstrated that more time on Optune predicted increased survival in patients who received Optune plus temozolomide compared to patients who received temozolomide alone. Optune is a noninvasive, portable medical device that delivers Tumor Treating Fields to people with GBM.
Novocure (NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their achievement and contribution to China’s health care ecosystem. Novocure, a global oncology company developing Tumor Treating Fields – a proprietary platform technology for the treatment of solid tumors – and Zai Lab, a Shanghai-based innovative biopharmaceutical company, announced in September an exclusive license agreement for Tumor Treating Fields, including the brand name Optune®, for use in oncology in Greater China and a global strategic development collaboration.
Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NVCR) today announced that they have received the Deal of the Year Award at the 9th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China. The annual award recognizes a groundbreaking collaboration, technology transfer, licensing, capital raising, M&A or joint venture that involves a Chinese company in the healthcare sector. In September of this year, Zai Lab and Novocure announced a strategic collaboration and an exclusive license agreement in the field of oncology by which Zai lab would develop and launch Novocure’s Tumor Treating Fields (TTFields) technology, under the brand name Optune®, in Greater China and to collaborate with Novocure in the global development of the product. TTFields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.
Presentations span 21 research areas with five oral presentations
Novocure announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating Fields in Greater China and address questions from the audience.
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018
Professor Palti invented Tumor Treating Fields and founded Novocure in 2000. “We have been honored to work so closely with Professor Palti for the last 18 years,” said Novocure CEO Asaf Danziger.
Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of co
The Tumor Treating Fields plus gemcitabine and nab-paclitaxel patient cohort showed progression free and one-year survivals that were more than double those of the gemcitabine and
Novocure (NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed GBM. Per Centers for Medicare & Medicaid Services (CMS) and Medicare policy, the two DME MACs will issue a single joint policy applicable in all DME regions.
Highlights include a data analysis of EF-14 that demonstrated an increased dose of Tumor Treating Fields to the tumor bed improved overall survival in GBM patients as well as safet
Novocure announced today that it will report financial results for the third quarter 2018 on Thursday, October 25, 2018, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2018, at 8 a.m.
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in
Novocure (NVCR), a global oncology company developing a proprietary platform technology called Tumor Treating Fields, and Zai Lab (ZLAB), a Shanghai-based innovative biopharmaceutical company, announced today an exclusive license agreement for Tumor Treating Fields, including the brand name Optune, in Greater China and a global strategic development collaboration. This agreement will enable Novocure to access the Chinese market and is intended to accelerate clinical trial enrollment.
NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Major U.S. equities were mixed on Wednesday with tech stocks posting worst daily drop since July dragging Nasdaq lower. The Dow Jones Industrial Average ...
Novocure (NVCR) announced final results from its STELLAR phase 2 registration trial in mesothelioma, demonstrating a significant extension in median overall survival among patients treated with Tumor Treating Fields plus standard of care chemotherapy compared to historical control data of patients who received standard of care chemotherapy alone. Malignant pleural mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months (95 percent CI, 12.1-25.8 months) compared to 12.1 months in a historical control.
NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...
Orgenesis (ORGS) is an underfollowed player in the biotech sector, but with growing revenue and high-profile clients and partners. Most recently, a prestigious healthcare institute Great Point Partners invested up to $25 million directly in their subsidiary and is acting as a key advisor for their global business expansion. Fundamentals are looking good at ORGS as revenue climbed 73% in fiscal Q2, over the year-ago period.
Novocure (NVCR) and US Oncology Research are collaborating on PANOVA-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.